Last reviewed · How we verify
Microscopic polyangiitis
Approved treatments
- Tavneos · Chemocentryx
Tavneos blocks the action of a chemical called C5a, which is involved in the body's inflammatory response. - Mabthera · Roche
- Mabthera · Roche
Monoclonal antibody targeting CD20 on B-lymphocytes, mediating cell lysis via CDC and ADCC. - Mabthera · Roche
Mabthera works by binding to the CD20 antigen on B-lymphocytes, triggering their destruction. - Tavneos · Chemocentryx
Tavneos blocks the action of a chemical called C5a, which is involved in inflammation and damage to blood vessels.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Microscopic polyangiitis patent landscape — cliff calendar, originator estates, attackable patents
- Microscopic polyangiitis treatment landscape brief
- Microscopic polyangiitis treatment updates RSS
Frequently asked questions about Microscopic polyangiitis
What drugs treat Microscopic polyangiitis?
Tracked treatments include Tavneos, Mabthera.
What is the treatment for Microscopic polyangiitis?
Standard treatment for Microscopic polyangiitis includes Tavneos, Mabthera. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Microscopic polyangiitis patent cliff · Microscopic polyangiitis CI report
- Treatment: Tavneos · Chemocentryx
- Treatment: Mabthera · Roche
- Treatment: Mabthera · Roche
- Treatment: Mabthera · Roche
- Treatment: Tavneos · Chemocentryx
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing